Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609379 | 1.00 | ADAM10 (0.46) | ADAM10GPR119STSTGFBR1MMP13 | |
| SCHEMBL4610407 | 0.86 | TSHR (0.45) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL4610406 | 0.86 | TSHR (0.45) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL4609431 | 0.85 | TSHR (0.44) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL4609429 | 0.85 | TSHR (0.44) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL4612477 | 0.83 | ADAM10 (0.42) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL6033492 | 0.83 | ADAM10 (0.50) | ADAM10MMP13KDM4ETSHRMAPK1 | |
| SCHEMBL4612474 | 0.83 | ADAM10 (0.42) | ADAM10PKMTSHRMAPK1 | |
| SCHEMBL4610016 | 0.83 | ADAM10 (0.50) | ADAM10MMP13KDM4ETSHRMAPK1 | |
| SCHEMBL5669290 | 0.76 | STS (0.44) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | ADAM10 101/4885GPR119 3790/4885STS 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.